DK0977565T3 - Farmaceutisk præparat omfattende en tricyklisk forbindelse med forbedret stabilitet og absorberbarhed og lavt irriationspotentiale - Google Patents

Farmaceutisk præparat omfattende en tricyklisk forbindelse med forbedret stabilitet og absorberbarhed og lavt irriationspotentiale

Info

Publication number
DK0977565T3
DK0977565T3 DK98904366T DK98904366T DK0977565T3 DK 0977565 T3 DK0977565 T3 DK 0977565T3 DK 98904366 T DK98904366 T DK 98904366T DK 98904366 T DK98904366 T DK 98904366T DK 0977565 T3 DK0977565 T3 DK 0977565T3
Authority
DK
Denmark
Prior art keywords
irriation
absorbability
potential
low
pharmaceutical composition
Prior art date
Application number
DK98904366T
Other languages
Danish (da)
English (en)
Inventor
Masayuki Yamanaka
Fumio Shimojo
Satoshi Ueda
Toshihiko Toyoda
Rinta Ibuki
Norio Ohnishi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of DK0977565T3 publication Critical patent/DK0977565T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
DK98904366T 1997-02-20 1998-02-18 Farmaceutisk præparat omfattende en tricyklisk forbindelse med forbedret stabilitet og absorberbarhed og lavt irriationspotentiale DK0977565T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3617297 1997-02-20
JP25635797 1997-09-22
PCT/JP1998/000665 WO1998036747A1 (en) 1997-02-20 1998-02-18 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
DK0977565T3 true DK0977565T3 (da) 2003-08-04

Family

ID=26375217

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98904366T DK0977565T3 (da) 1997-02-20 1998-02-18 Farmaceutisk præparat omfattende en tricyklisk forbindelse med forbedret stabilitet og absorberbarhed og lavt irriationspotentiale

Country Status (21)

Country Link
US (1) US6387918B1 (de)
EP (1) EP0977565B1 (de)
JP (1) JP3396888B2 (de)
KR (1) KR100490357B1 (de)
CN (1) CN1178656C (de)
AR (1) AR011846A1 (de)
AT (1) ATE237325T1 (de)
AU (1) AU727337B2 (de)
BR (1) BR9807234B1 (de)
CA (1) CA2282345C (de)
DE (1) DE69813542T2 (de)
DK (1) DK0977565T3 (de)
EA (1) EA003580B1 (de)
ES (1) ES2193515T3 (de)
HK (1) HK1027957A1 (de)
HU (1) HU226163B1 (de)
IL (1) IL131298A (de)
NO (1) NO325103B1 (de)
PT (1) PT977565E (de)
TW (1) TW450810B (de)
WO (1) WO1998036747A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29262A (id) * 1998-04-27 2001-08-16 Fujisawa Pharmaceutical Co Komposisi farmasi
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
NZ532769A (en) 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
ATE531368T1 (de) 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
DE602004028023D1 (de) 2003-08-29 2010-08-19 Lifecycle Pharma As Tacrolimus enthaltende feste dispersionen
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US7672006B2 (en) * 2006-02-22 2010-03-02 Xerox Corporation Multi-marking engine printing platform
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
JP2009533440A (ja) * 2006-04-10 2009-09-17 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ拮抗薬塩
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
EP2167033B1 (de) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Tacrolimus enthaltende orale dosisform zur einmal täglichen einnahme
WO2010041684A1 (ja) 2008-10-08 2010-04-15 高田製薬株式会社 タクロリムス外用剤
AR081520A1 (es) 2010-02-17 2012-10-03 Lifecycle Pharma As Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP2789335B1 (de) * 2011-12-07 2017-02-15 Hisamitsu Pharmaceutical Co., Inc. Klebepflaster
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
AU2016308568A1 (en) 2015-08-19 2018-02-22 Vivus Llc Pharmaceutical formulations
EP3641725A1 (de) 2017-06-23 2020-04-29 The Procter and Gamble Company Zusammensetzung und verfahren zur verbesserung der erscheinung der haut
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
CN112437657A (zh) 2018-07-03 2021-03-02 宝洁公司 处理皮肤状况的方法
EP4157206A1 (de) 2020-06-01 2023-04-05 The Procter & Gamble Company Verfahren zur verbesserung der penetration einer vitamin-b3-verbindung in die haut
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
EP4301380A1 (de) 2021-03-03 2024-01-10 Sana Biotechnology, Inc. Immunsuppressive therapien zur verwendung mit herzmuskelzelltherapien sowie zugehörige verfahren und zusammensetzungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
DE69125230T2 (de) * 1990-09-04 1997-07-10 Fujisawa Pharmaceutical Co Tricyclische Verbindungen enthaltende Salben
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
CN1089233C (zh) * 1994-10-26 2002-08-21 诺瓦蒂斯有限公司 药物组合物

Also Published As

Publication number Publication date
AU727337B2 (en) 2000-12-07
CN1178656C (zh) 2004-12-08
WO1998036747A1 (en) 1998-08-27
AR011846A1 (es) 2000-09-13
HUP0000979A3 (en) 2002-10-28
HUP0000979A1 (hu) 2000-10-28
US6387918B1 (en) 2002-05-14
DE69813542T2 (de) 2003-11-20
CA2282345A1 (en) 1998-08-27
BR9807234A (pt) 2000-04-25
EP0977565A1 (de) 2000-02-09
JP3396888B2 (ja) 2003-04-14
KR20000070824A (ko) 2000-11-25
EA199900749A1 (ru) 2000-04-24
IL131298A0 (en) 2001-01-28
ATE237325T1 (de) 2003-05-15
NO325103B1 (no) 2008-02-04
IL131298A (en) 2004-06-20
EP0977565B1 (de) 2003-04-16
ES2193515T3 (es) 2003-11-01
BR9807234B1 (pt) 2013-11-05
DE69813542D1 (de) 2003-05-22
US20020032212A1 (en) 2002-03-14
TW450810B (en) 2001-08-21
JP2000513739A (ja) 2000-10-17
AU6228998A (en) 1998-09-09
KR100490357B1 (ko) 2005-05-17
HU226163B1 (en) 2008-05-28
NO994003D0 (no) 1999-08-19
EA003580B1 (ru) 2003-06-26
PT977565E (pt) 2004-01-30
CN1252721A (zh) 2000-05-10
HK1027957A1 (en) 2001-02-02
CA2282345C (en) 2008-10-21
NO994003L (no) 1999-10-19

Similar Documents

Publication Publication Date Title
DK0977565T3 (da) Farmaceutisk præparat omfattende en tricyklisk forbindelse med forbedret stabilitet og absorberbarhed og lavt irriationspotentiale
EE04904B1 (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
NO307182B1 (no) Farmasoeytiske blandinger og tricykliske forbindelser
NO20002359L (no) Adenosinderivater og farmasoytisk sammensetning inneholdende derivatene
FI944832A0 (fi) Farmaseuttinen koostumus
FI955311A (fi) Farmaseuttinen koostumuspohja
BR9200058A (pt) Composto e composicao farmaceutica
DE69524592D1 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
FI960867A0 (fi) Bentsatsepiinijohdannainen, sen farmaseuttinen seos ja välituote
BR9709947A (pt) Novo derivado tiofeno e composição farmacêutica do mesmo
ITMI932540A0 (it) Composizione farmaceutica
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
BR9509688A (pt) Composto e composição farmacêutica
DE4294862T1 (de) Pharmazeutische Komposition
HUP0003189A2 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
BR9507768A (pt) Composição farmacêutica
ID25857A (id) Komposisi farmasi
ID18698A (id) Komposisi farmasi
DE69725166D1 (de) Substituierte benzamidderivate und diese enthaltende pharmazeutische zusammensetzung
LV10579A (lv) Farmaceitiska kompozicija
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
DE69900336D1 (de) Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen
HUP0003765A3 (en) Crambescidin derivatives and pharmaceutical compositions containing them
BR1101151A (pt) Compostos e composição farmacêutica